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Summary
Acute inflammation is a complex and tightly regulated homeostatic process
that includes leucocyte migration from the vasculature into tissues to
eliminate the pathogen/injury, followed by a pro-resolving response
promoting tissue repair. However, if inflammation is uncontrolled as in
chronic diseases such as rheumatoid arthritis (RA), it leads to tissue damage
and disability. Synovial tissue inflammation in RA patients is maintained by
sustained activation of multiple inflammatory positive-feedback regulatory
pathways in a variety of cells, including myeloid cells. In this review, we will
highlight recent evidence uncovering biological mechanisms contributing to
the aberrant activation of myeloid cells that contributes to perpetuation of
inflammation in RA, and discuss emerging data on anti-inflammatory
mediators contributing to sustained remission that may inform a novel
category of therapeutic targets.
Keywords: arthritis (including rheumatoid arthritis), cytokines, inflamma-
tion, macrophage
Introduction
Rheumatoid arthritis (RA) develops from breach-of-
tolerance to self-antigens and the generation of autoantibod-
ies to post-translationally modified self-proteins, e.g. via cit-
rullination and carbamylation, to create anti-modified
protein autoantibodies (AMPA), that probably initiate
inflammation and bone damage. RA pathogenesis comprises
genetic predisposition (100 alleles mainly with immune
function, e.g. human leucocyte antigen D-related 4 (HLA-
DR4): DRB1*0401) [1], and epigenetic changes including
DNA/histone modification and microRNA deregulation.
Environmental factors such as cigarette smoking associate
with disease perhaps by enhancing post-translational citrulli-
nation forming new epitopes that bind preferentially to
HLA-DR molecules (e.g. DRB1*0401) compared with the
native form. This, acting in concert with less-understood
stimuli such as infection, exposure to silica particles or an
altered microbiota, lead to dendritic cell (DC)-orchestrated
(or potentially B cell) activation of citrullinated peptide-
specific T helper type 1 (Th1)-producing IFN-g and
Th17-producing IL-17 and granulocyte–macrophage
colony-stimulating factor (GM-CSF) and follicular T lym-
phocytes, which facilitate production of autoantibodies
[e.g. anti–citrullinated protein antibody (ACPA)].
Initiation of autoimmunity precedes onset of joint
inflammation and progression to joint degradation, which
additionally involves epigenetically altered synovial fibro-
blasts; the main producers of interleukin (IL)-6 and of met-
alloproteinases that degrade cartilage and monocyte-derived
inflammatory macrophages; and the main producers of
pathogenic cytokines, notably tumour necrosis factor
(TNF)-a [2,3]. The factors that initiate the localized inflam-
mation in the joint remain poorly understood. It is proposed
that joint injury or transient infection can activate the vascu-
lature and allow access of autoantibodies. These form
immune complexes with joint tissue antigens and activate
stromal cells, resident macrophages, mast cells and osteo-
clasts to release vasoactive mediators and chemokines
recruiting leucocytes and exacerbating the inflammation
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[2,3]. For example, monocytes infiltrating the synovium dif-
ferentiate locally to macrophages and are the main source of
TNF, IL-1b, IL-6 and GM-CSF [4]. Alternate initiating mod-
els propose ACPA-binding osteoclasts and inducing local IL-
8 production and neutrophil recruitment and this inflam-
mation onset [5]. DCs, mainly the CD1c1 subpopulation,
contribute to the proinflammatory cytokine milieu in the
synovium and activate autoreactive T cells [6].
The majority of current RA treatments target either these
inflammatory mediators or their critical signalling path-
ways, e.g. TNF (soluble receptor or blocking antibodies),
IL-6R (blocking antibody), Janus kinases (small molecule
inhibitors) or target adaptive immunity, e.g. B cells (anti-
CD20 antibody) or block the interaction between antigen-
presenting cells and T cells [cytotoxic T lymphocyte
antigen-4 (CTLA-4)]. These treatments retard disease pro-
gression, but do not reverse underlying autoimmunity and
do not cure the disease. Regardless of treatment, 30–50%
of patients exhibit an inadequate response, and among
those who respond, 50% relapse within weeks after treat-
ment cessation [2], highlighting the need for novel treat-
ment strategies. Obvious targets based on murine model
predictions have, unexpectedly, failed. For example, thera-
pies targeting either IL-17 or the common subunit of IL-
12/IL-23 (cytokines that drive Th1 and Th17, respectively)
did not improve RA disease activity [7]. Thus, a better
understanding of the pathogenesis of RA is required to
prosper new therapies. This review will describe recent evi-
dence uncovering biological mechanisms contributing to
the aberrant activation of myeloid cells that leads to perpet-
uation of inflammation and chronicity in RA. We will
review recent evidence for inflammatory mediators that are
novel therapeutic targets, e.g. GM-CSF, and describe novel
functions of well-described inflammatory mediators, e.g.
TNF, that could explain their contribution to the chronicity
of RA. We will also discuss emerging data describing the
role of anti-inflammatory mediators in sustained remission
in RA patients, and how these may lead to the development
of new therapeutics.
Synovial myeloid cells are key perpetuators
of inflammation
Inflammation is a complex homeostatic process that
includes leucocyte migration from the vasculature into tis-
sues. This is followed by activation of negative-feedback
mechanisms that should attenuate inflammation to limit
collateral damage and initiate repair. The success of thera-
pies against myeloid cell derived mediators and ex-vivo
studies suggest that synovial inflammation is maintained
by sustained activation of multiple inflammatory positive-
feedback loops in myeloid cells [8,9] fuelled by epigeneti-
cally modified tissue-resident cells [10] and effector path-
ways of autoimmunity [5].
Macrophages
Animal models show that most healthy tissues contain
tissue-resident macrophages that originate from prenatal
precursors and are essential in maintaining tissue homeo-
stasis, e.g. by removing apoptotic cells. In response to infec-
tion/injury, a different tissue macrophage population
differentiates from infiltrating monocytes and these mount
an inflammatory response [11]. Experimental data show
that mouse synovium contains a tissue-resident macro-
phage population that is crucial in limiting inflammatory
responses in the synovium, while monocyte [both lympho-
cyte antigen 6 complex, locus C1 (Ly6C)1 and Ly6C–]-
derived macrophages drive the inflammatory response and
the severity of experimental arthritis [12,13]. Transcrip-
tomic data suggest that these two subpopulations of mac-
rophages respond differently to ‘on-demand’ signals
derived from a changing tissue environment, which can
polarize macrophages on the spectrum from proinflamma-
tory (M1 activation spectrum) to anti-inflammatory and
repair (M2 activation spectrum) [12]. This has been con-
firmed elegantly in a recent paper showing that tissue-
resident macrophages (e.g. in the peritoneum, plural cavity
or lung) have a Kr€uppel-like factor 2 (KLF2)/KLF4-driven
transcriptomic programme that facilitates apoptotic cell
uptake while negatively regulating proinflammatory Toll-
like receptor (TLR) signalling [14]. Similarly, in mouse
models of arthritis, tissue-resident macrophages and
monocyte-derived macrophages exhibit distinct transcrip-
tomic profiles at the peak of inflammation. Monocyte-
derived macrophages showed the M1-type phenotype with
high levels of proinflammatory mediators, e.g. IL-1b, IL-
12, CD80 and CD86, compared to resident macrophages,
while the latter up-regulated efferocytosis receptors [e.g.
MER proto-oncogene, tyrosine kinase (MerTK), CD36,
CD163]. During the resolution of experimental arthritis,
there is a phenotypical change of monocyte-derived macro-
phages from a pro- to anti-inflammatory (M2 spectrum)
that is induced by an as-yet-unidentified signal [12].
In human healthy joints, the synovial lining layer
expresses tissue-resident macrophages that contain phago-
somes and express the scavenger receptor CD163, suggest-
ing that, similar to their mouse counterparts, they are
strongly phagocytic [15,16]. They also express the major
histocompatibility complex (MHC)-II, IL-1R-antagonist,
the inhibitor of bone degradation, osteoprotegerin (OPG)
[15,17,18], but they lack proinflammatory cytokines (e.g.
TNF and IL-1b) and the bone resorption-inducing cyto-
kine, receptor activator of nuclear factor kappa-B ligand
(RANKL) [18], suggesting a joint-protective function dur-
ing inflammation and damage. During RA development,
driven by an influx of blood monocytes [19], the number
of macrophages increases, particularly in the sublining
layer, and they polarize into a proinflammatory phenotype
upon activation by local signals. The hypertrophic
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synovium creates a hypoxic environment [20], and
recruited macrophages adapt to the low oxygen levels by
up-regulating hypoxia-inducible transcription factor 1
(HIF-1a) that mediates a switch in their energy metabo-
lism from an oxidative phosphorylation to anaerobic gly-
colysis, and supports their proinflammatory activation
[21,22]. Myeloid-specific deletion of HIF-1a reduces joint
swelling and inflammatory activity in a murine arthritis
model [23]. ACPA and citrullinated fibrinogen complex in
the synovium can induce TNF production via synergistic
binding to FcgP and TLR-4 [24]. Oxidized oxysterols,
enriched in RA synovial fluid, can bind to the transcription
factor liver X receptor (LXRa) in synovial macrophages
and enhance damage-associated molecular patterns
(DAMPs)-induced TNF, IL-6, IL-1b and granulocyte–mac-
rophage colony-stimulating factor (G-CSF) production
[25]. Memory T cells, recruited and expanded in synovial
fluid by cytokines (e.g. IL-15, IL-6 and TNF), trigger sub-
stantial production of TNF by macrophages upon direct
integrin-mediated contact [26,27], while IFN-g released by
citrullinated-peptide autoreactive T cells [28] can enhance
the ability of macrophages to present antigen and thereby
their potential to activate autoreactive memory T cells.
Activated by the local stimuli, RA synovial macrophages
produce predominantly chemokine (C-X-C motif) ligand
(CXCL)4 and CXCL7 (chemokines recruiting neutrophils
and blood monocytes), particularly in early RA [29], and
TNF [30] and other proinflammatory cytokines (e.g. IL-1b
[31] and IL-6 [32]) and alarmins S100A8/9 [33] through-
out disease progression. Their proinflammatory activation
is co-regulated by nuclear factor kappa B (NF-jB), inter-
feron regulatory factor 5 (IRF5), signal transducer and acti-
vator of transcriptions (STATs), LXRa and HIF-1a
transcription factors at the transcriptional level [20,25,34],
and by microRNA155 and microRNA146 at the post-
transcriptional level [35,36]. In multi-cellular organisms,
miRNAs are small non-coding RNAs that repress their tar-
get mRNAs by binding to complementary sequences at the
3’ untranslated regions [37]. MicroRNA155 was identified
as a key positive regulator of the inflammatory response
that is counterbalanced by the action of microRNA146 in
myeloid cells [38,39]. MicroRNA155 expression is
increased significantly in RA synovial tissue macrophages
and in synovial fluid and blood monocytes, compared to
non-inflammatory synovial tissue and to healthy blood
monocytes. Expression of microRNA155 in RA monocytes
correlates strongly with disease activity [40]. The proin-
flammatory environment in arthritic joints (e.g. DAMPs,
TNF, IL-1b, oxysterols and contact with T cells) triggers
and maintains microRNA155 expression in synovial fluid
monocytes and in tissue macrophages, and this locks these
cells into a chronic proinflammatory state [35,40–42].
MicroRNA155 represses Src homology 2-containing inosi-
tol phosphatase-1 (SHIP-1), which is a negative-regulator
of the phosphoinositide 3-kinase/Akt pathway, and a
negative-regulator of TLR signalling. Moreover, high
expression of microRNA155 leads to the repression of
CCR2 in monocytes, and this probably contributes to the
retention of synovial monocytes in the synovium [40].
Neutralization of microRNA155 in synovial fluid cells abol-
ished their TNF production and de-repress the expression
of SHIP-1, thus restoring the homeostatic negative-
feedback mechanism limiting inflammation [35] (Fig. 1).
Dendritic cells
DCs maintain immune tolerance to self-antigens in healthy
tissues. During infection they undergo maturation, induced
by ligand binding of pathogen-associated molecules to cell
receptors (e.g. TLR), and this enables them to activate the
immune response to promote pathogen elimination. When
the infection is cleared, DCs then reinstate homeostasis to
prevent further tissue damage and potential for bystander
activation of autoreactive T cells. Tolerance and immune
homeostasis are mediated by immature and tolerogenic
DCs characterized by unique phenotypes. These include
low expression of co-stimulatory molecules (e.g. CD40,
CD80, CD86) and the absence of production of proinflam-
matory mediators (e.g. IL-12). They express inhibitory
receptors [e.g. programmed death ligand 1 (PD-L1),
CD95L] and produce inhibitory mediators preferentially
[e.g. IL-10, TGF-b, IL-27, prostaglandin E2 (PGE2) and
indoleamine 2,3-dioxygenase]. These DC phenotypes pre-
vent activation of autoreactive T cells and down-regulate
adaptive and inflammatory immune responses by several
mechanisms, including: by inducing apoptosis or anergy in
effector T cells, by expansion of thymus-derived regulatory
T cells (tTreg) and by generation of new regulatory T cells
(e.g. Treg1). Regulatory T cells can limit the activation of
antigen-specific effector T lymphocytes and the activation
of proinflammatory macrophages. In addition, they can
feedback-inhibit DC activation, thus restraining the
immune response and reinstating homeostasis. DCs are
categorized broadly as plasmacytoid DCs or conventional
myeloid DCs that differ in location, the molecular signals
they recognize and the profile of mediators they produce
[43,44].
CD1c1 dendritic cells in humans, and their murine
counterparts CD11c1CD11b1 dendritic cells, are the most
abundant subpopulation of myeloid DCs in tissues where
their immune-regulatory immature/tolerogenic phenotype
supports regulatory T cells and maintains tissue homeosta-
sis [45–47]. Upon infection they mature, particularly upon
TLR-7/8 ligation, and initiate an immune response to
pathogens by activation of Th1 and Th17 lymphocytes
[48,49]. Dendritic cells are found in the healthy synovium
and localize mainly in the perivascular areas of the sublin-
ing layer [15], probably contributing to maintaining toler-
ance in the joint. Evidence points towards a significant
role of CD1c1 DCs in the onset and progression of RA.
Role of myeloid cells in rheumatoid arthritis
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ACPA-positive(1) healthy individuals, at risk of developing
RA, have substantially increased numbers of CD1c1DCs in
the lymph nodes that drain joint tissue, compared with
ACPA-negative(–) healthy individuals [50]. This suggests
their potential involvement in the regulation of early
breach-of-self-tolerance in preclinical RA. Thereafter, syno-
vial tissue and fluid from patients with active RA are
enriched in CD1c1 DCs that have an activated (mature)
phenotype, indicated by increased expression of co-
stimulatory molecules such as CD86, CD80 and CD40
compared to blood cells. They can expand autologous
memory Th1/Th17 cells [51–53] and contribute to synovial
inflammation by producing TNF upon TLR-7/8 activation
[54,55] and chemokines [51]. It is postulated that their
mature phenotype in the synovium is mediated by thymic
stromal lymphopoietin (TSLP) produced locally in the
inflamed joint by activated fibroblasts-like synoviocytes
[52].
Commensurate with an increased number of CD1c1 in
joint draining lymph node (DLN) of individuals at risk of
developing RA, circulating CD1c1 of patients with early
RA are changed epigenetically and show increased
expression of microRNA34a, which is sustained in estab-
lished RA and up-regulated further in synovial tissue
CD1c1 cells. This, correlated with decreased expression of
its mRNA target Axl, a tyrosine kinase receptor that
together with other family members, Tyro3 and MerTK,
are indispensable in limiting DC activation [56]. Micro-
RNA34a has been identified as an evolutionarily conserved
key regulator of innate immunity in Drosophila [57].
Recently, it was shown that the microRNA34a/GAS6-Axl
pathway is important for optimal control of the immune
response [58]. CD1c1 DC stimulation by TLRs leading to
DC-driven effector T cell activation is commensurate with
down-regulation of microRNA34a and release of its epige-
netic control of Axl in DCs. Axl, upon binding of its ligand
GAS6, induces SOCSs (suppressor of cytokine signalling)
and terminates DC proinflammatory cytokine production
and DC-driven T cell activation. With age, both Axl defi-
cient(–/–) and GAS6–/– mice develop an autoimmune phe-
notype spontaneously. Axl–/– mice have DCs with an
activated phenotype, and develop increasing serum titres of
autoantibodies resembling the early breach-of-tolerance to
self-antigen characteristic of preclinical phase RA [59],
Fig. 1. Mechanisms of macrophage cell activation promoting chronic inflammation in rheumatoid arthritis. Synovial macrophages differentiate
from epigenetically reprogrammed monocytes that migrate from the circulation into synovial fluid and tissue. Synovial damage-associated
molecular patterns (DAMPs) (e.g. fibronectin) binding to Toll-like receptors (TLRs), anti-citrullinated protein antibody (ACPA) or rheumatoid
factor binding to Fc-gamma receptor (FcyR), oxysterols, hypoxia and direct integrin-mediated and cytokine-mediated crosstalk with T cells and
fibroblast-like synoviocytes (FLSs) promote synovial macrophage proinflammatory activation. This response is co-ordinated by several
transcription factors and integrated by epigenetic regulators, e.g. microRNA155 that inhibits a negative-regulator of inflammation Src homology
2-containing inositol phosphatase-1 (SHIP1); thus, maintains synovial macrophages chronic activation. ECM 5 extracellular matrix proteins;
GM-CSF 5 granulocyte-macrophage colony-stimulating factor; HIF1a 5 hypoxia-inducible factor 1-alpha; IgS 5 Ig-superfamily;
IRF5 5 interferon regulatory factor 5; LXRa 5 Liver X Receptor alpha; miR 5 microRNA; MMPs 5 metalloproteinases; NF-jB 5 nuclear
factor kappa B; RF: rheumatoid factor; STAT 5 signal transducer and activator of transcription. This figure presents a novel development of
concepts that were presented in our previous review [75].
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while GAS6–/– mice develop a spontaneous increase in
effector Th17 over Tregs that leads to gut inflammation
[60]. The production of proinflammatory cytokines and
expression of MHC class II by DCs could be inhibited by
gene-silencing of microRNA34a, and in keeping with this,
microRNA34a–/– mice do not develop collagen-induced
arthritis, and their DCs have diminished interaction with
effector antigen-specific T cells, reduced production of
proinflammatory cytokines and did not support the devel-
opment of pathogenic Th17 cells. These functions were
attributable to the corresponding increased expression of
deregulated Axl [58]. Neutralization of the increase expres-
sion levels of microRNA34a in CD1c1DCs from RA
patients inhibited proinflammatory cytokine production
by reinstating the expression of the Axl inhibitory pathway.
Consistent with this, van den Brand et al. [61] showed that
activation of the Axl pathway by GAS6 inhibited experi-
mental arthritis. Thus, optimal activation of the micro-
RNA34/GAS6–Axl pathway is required for DC control of
the adaptive immune response, and low expression of Axl
in CD1c1 DCs in rheumatoid arthritis patients could con-
tribute to the initiation and perpetuation of disease by
facilitating the activation of autoreactive T cells upon initial
bystander trigger, e.g. infection or tissue damage. This
highlights the microRNA34a/GAS6-Axl pathway for poten-
tial therapeutic targeting in RA.
The results of two recent phase I clinical trials showing
safety and efficacy of passive transfer of autologous, in
vitro-generated tolerogenic DCs for RA therapy, suggest
that targeting DCs to reinstate immune tolerance to citrul-
linated peptides is a promising therapeutic strategy [62,63].
However, there are challenges, including the reduced likeli-
hood of treatment response in RA patients with long-
standing disease, and the selection of autoantigens for the
generation of effective tolerogenic DCs ex vivo (Fig. 2).
MicroRNAs offer therapeutic potential either as direct
targets or by ‘identifying’ tractable and plausible pathways.
Therapeutic targeting of microRNAs has been successful in
some cancers, infectious diseases and recently models of
tendinopathy [64,65]. Inhibition of microRNA155 with
specific anti-miR-155 improved the clinical severity of
experimental arthritis significantly [66] However, the pros-
pect of non-cell/tissue-specific targeting microRNA155 in
RA may be unrealistic. MicroRNA155 is key in
mounting protective antibody production, regulation of
lipid metabolism in the liver and the repair process.
MicroRNA155-deficient mice show reduced germinal
centre formation [67], liver steatosis [36] and lung fibrosis
[68]; thus, systemic targeting of microRNA155 may have
detrimental effects. Activation of inhibitors of proinflam-
matory cell activation that are repressed by microRNA155,
e.g. SHIP-1, by specific activators might be a safer option
[69]. The SHIP-1 activator (AQX-1125) used in clinical
trials in chronic obstructive pulmonary disease (COPD)
and allergic asthma demonstrated a favourable safety
profile and anti-inflammatory activity (trial number:
NCT01954628).
The microRNA34/GAS6–Axl axis may resemble the
PDL1/PD1 or CTLA-4/B7 pathways in the mechanism by
which they regulate the balance between immunosuppres-
sion (cancer) and immunostimulation (autoimmunity).
The recently developed PDL1/PD1 pathway blockade is a
highly promising therapy that has elicited anti-tumour
responses and long-term remissions in a broad spectrum of
cancers by activating anti-cancer-specific immune response
[70]. However, these patients not infrequently exhibit side
effects that include developing autoimmune disease
[71,72]. In contrast to RA, microRNA34a is down-regulated
in stromal cell cancers leading to de-repression of target
anti-apoptotic proteins and cell-cycle inhibitors and causing
cancer cell expansion [73]. The microRNA34amimic
MRX34 (Mirna Therapeutics, Austin, TX, USA) is currently
Fig. 2. Mechanisms of dendritic cell activation promoting chronic
inflammation in and adaptive immunity in rheumatoid arthritis
(RA). Local production of GM-CSF and TSLP (e.g. by FLS) and
release of DAMPs activate synovial CD1c1 dendritic cells (DCs) to
release proinflammatory mediators and to stimulate autoreactive T
cells. Synovial CD1c1 and their blood precursors express high levels
of epigenetic regulator microRNA34a that sustains their
proinflammatory and T helper type 17 (Th17) differentiating
cytokine production, antigen presentation by major
histocompatibility complex (MHC) class II and interaction with T
cells. This is, in part, mediated by microRNA34a- induced repression
of Axl. Axl, upon binding of its ligand GAS6, induces SOCSs
(suppressor of cytokine signaling) and terminates DC
proinflammatory cytokine production and DC-driven T cell
activation. Thus, low expression of Axl in CD1c1DCs in RA patients
could contribute to the initiation and perpetuation of disease by
facilitating the activation of autoreactive T cells and cytokine
production upon initial bystander trigger of dendritic cells (DC), e.g.
infection or tissue damage. AXL 5 AXL-receptor tyrosine kinase;
DAMPs 5 damage-associated molecular patterns;
ECM 5 extracellular matrix proteins; FLS 5 fibroblast-like
synoviocytes; GAS6 5 growth arrest-specific 6; GM-
CSF 5 granulocyte-macrophage colony-stimulating factor;
miR 5 microRNA; TSLP 5 thymic stromal lymphopoietin.
Role of myeloid cells in rheumatoid arthritis
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being tested in several solid and haematological malignan-
cies [64]. Its epigenetic target Axl is de-repressed in cancer
cells and in immune cells of cancer patients and this contrib-
utes to immunosuppression and cancer metastasis. This
ying–yang role of the microRNA34a/GAS6-Axl pathway in
cancer and autoimmunity suggests that manipulation of this
pathway has the potential to rebalance the immune system
[74]. Thus, therapeutic stimulation of Axl functions in RA
DCs to rebalance the immune system could bring clinical
improvement in RA, similar to CTLA-4 therapy, albeit with
careful cancer risk factor monitoring.
Inflammatory mediators
The contribution of macrophage- and inflammatory DC-
derived cytokines to RA pathogenesis has been reviewed
extensively [4,7,9,75]. Briefly, TNF is bioactive as a trans-
membrane protein as well as a homotrimeric secreted mole-
cule [76]. During inflammation, TNF functions by binding
two distinct TNF receptors, p55TNFR (TNFRI) and
p75TNFR (TNFRII) [77]. TNF increases vascular permeabil-
ity and enhances tissue ingress of cells, immunoglobulin
(Ig)G/IgM-immune complexes and complement [78]. TNF
synergizes with IL-1b to induce synovitis by induction of che-
mokines, cytokines, e.g. IL-6, and prostaglandins by various
cells, causes cartilage destruction by triggering the production
of metalloproteinases by synovial fibroblasts and causes bone
resorption by increasing the differentiation of osteoclasts
[79]. Commensurate with this, transgenic over-expression of
TNF triggers the development of chronic synovitis [80]. TNF
also prevents resolution actively, e.g. by impacting negatively
the function of regulatory T cells [81], by inducing forkhead
box protein 3 (FoxP3) degradation [82] and by inhibiting the
development of TLR tolerance [83]. An elegant paper led by
Ivaskhiv [83] showed that TNF co-operates with IFN-a in
preventing the development of tolerance to TLR stimuli. TLR
tolerance is a key process in limiting collateral tissue damage
during the normal immune response. TNF preconditioning
induces tolerance and limits potentially toxic induction of
NF-jB target genes encoding inflammatory molecules, while
enabling expression of genes encoding anti-viral molecules
upon LPS stimulation. However, TNF in the presence of IFN-
a reprogrammes the human macrophage epigenome to
increase NF-jB-driven inflammatory responses to TLR stim-
ulation. Type I interferons potentiate the inflammatory func-
tion of TNF by preventing the silencing of genes encoding
inflammatory molecules, including IL-6, IL-8, CCL4, CCL4
and CCL20. Thus, this cross-talk between DAMPs (e.g. prod-
ucts of joint damage [84], IFN-a/b (e.g. released upon stimu-
lation with RNA from necrotic joint cells [85] and TNF could
contribute to the failure of resolution in the inflammatory
RA synovium [83].
Recently, a novel survival role for cell-intrinsic-TNF in
circulating monocytes was described. Mouse monocytes
selectively deficient for TNF or TNF receptors are out-
competed by their wild-type counterpart due to their
decrease survival rate and reduced migration to injured tis-
sues [86]. This novel mechanism can contribute to the per-
sistence of inflammatory monocytes and/or macrophages
in RA in a TNF-rich environment. Synovial fluid mono-
cytes from RA patients are resistant to spontaneous apo-
ptosis and to apoptosis mediated by an agonistic anti-Fas
antibody, compared to blood monocytes of healthy donors.
This resistance is due to the progressive inhibition of
caspace 10 (CASP10) and apoptotic protease activating fac-
tor 1 (APAF1) by the increasing levels of microRNA155
[87] that is inducible by TNF.
Another cytokine that is essential in the development of
RA, as evidenced by the success of the anti-cytokine ther-
apy, is IL-6. IL-6 is produced by various cells, including
synovial fibroblasts, macrophages and inflammatory DCs.
IL-6 signals through IL-6Ra/gp130. IL-6Ra expression is
restricted to leucocytes and a few other cell types, and is
functionally active only after combined ligation with
gp130. A soluble form of the receptor (s-IL6Ra) is shed by
cells in the circulation and the IL-6/sIL-6Ra can dimerize
with membrane gp130 present on IL-6Ra-negative cells
and stimulate these cells. IL-6 regulates leucocyte recruit-
ment in vivo by activating endothelial cells to increase
adhesion molecule expression and produce CCL2 [88], and
promote the transition from neutrophilic to monocytic
inflammation by shifting the profile of chemokines pro-
duced [89]. IL-6 also regulates T cell infiltration by govern-
ing the production of appropriate chemokines, e.g.
CXCL10, CCL11, CCL4, CCL17 and the expression of their
receptors CCR3, CCR4, CCR5 and CXCR3 on T cells [90].
IL-6 is indispensable for Th17 and follicular T cell differen-
tiation and survival, and for antibody production by B cells
[4]. In animal models of arthritis, increased IL-6 is detected
from the very early phases of disease consistent with its role
in modulating leucocyte recruitment in vivo [91]. In addi-
tion, analysis of blood samples obtained from ACPA1 indi-
viduals at risk of developing RA but without clinical
symptoms showed that the concentration of IL-6 was
increased compared to heathy ACPA– subjects [92]. An
increased expression of an IL-6-induced gene signature was
found in circulating T cells of early RA [93], while an
increased expression of IL-6 mRNA was found in circulat-
ing CD1c1 DCs which correlated negatively with lower
expression of Axl, which is the negative regulator of DC
activation [58]. These observations suggest the potential
involvement of IL-6 in DC/T cell interaction in early RA.
Novel therapies targeting myeloid cell relevant
anti-inflammatory mediators
In the synovium, the polarization of monocyte-derived
macrophages and dendritic cells can be shaped by their
interaction with synovial CD41 T cells [94] and synovial
fibroblasts that are epigenetically reprogrammed to
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produce a wide range of mediators [95]; both cell types pro-
duce GM-CSF that potentiates the proinflammatory activa-
tion of macrophages [96,97] and the differentiation of
inflammatory DCs. It was shown recently that GM-CSF
induces metabolic reprogramming of myeloid cells that is
critical for an increase production of proinflammatory cyto-
kines following TLR restimulation. GM-CSF increases the
macrophage glycolytic metabolism by a c-Myc-dependent
mechanism. In addition, GM-CSF-primed macrophages
have an enhanced activation of the mevalonate pathway due
to an increase in expression of enzyme 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR) [98] and due indi-
rectly to substrate flux from increased glycolysis. Inhibition
of the mevalonate pathway by simvastatin completely abol-
ished GM-CSF priming. In addition, GM-CSF drives CCL17
production by acting through an IRF4-dependent pathway
in human monocytes. In murine models of arthritis, GM-
CSF up-regulated IRF4 and thus CCL17 production by
enhancing the expression of the epigenetic enzyme JMJD3
demethylase, which activates IRF4 expression. CCL17 medi-
ated the proinflammatory and algesic actions of GM-CSF
[96] that was independent of T/B cells and TNF/IL-1b. GM-
CSF also regulates the survival of neutrophils and primes
them for the production of reactive oxygen species, thus
contributing to neutrophil-mediated pathological processes
including NETosis [99]. Based on strong preclinical data,
biologically based antagonists of GM-CSF or its receptor
have been developed [100]. RA patients have elevated GM-
CSF concentrations in serum and synovial fluid and high
expression of GM-CSF-R in inflamed synovial tissue
[101,102]. Moreover, synovial fluid TNF and IL-1 further
amplify the production GM-CSF [103].
Several clinical trials were performed to test the efficacy
and safety of therapeutic antibody against the GM-CSF
receptor in patients with RA [4]. The GM-CSF-R is com-
posed of a specific ligand-binding a-chain (GM-CSFRa)
and a signal-transducing b-chain (GM-CSFRb), which
transmits the intracellular Janus kinase (JAK)2/STAT-3/
STAT-5 signalling. Mavrilimumab (CAM-3001) is a fully
human IgG4 monoclonal antibody that binds the GM-
CSF-R and antagonizes the binding of GM-CSF [4]. More-
over, it internalizes with the GM-CSF-R and reduces recep-
tor recycling, thereby reducing the receptor expression on
the cell surface. The benefit of blocking the GM-CSF-R was
demonstrated first by Greven et al. [100] in preclinical
studies using the collagen-induced arthritis mouse model.
Treatment with anti-mouse GM-CSF-R neutralizing anti-
body (CAM-3003) inhibited clinical signs and symptoms
of arthritis dose-dependently and greatly reduced the num-
ber of activated macrophages within the inflamed syno-
vium [100]. In a phase 1 study of RA patients,
mavrilimumab administered intravenously was safe and
reduced C-reactive protein (CRP) and erythrocyte sedi-
mentation rate (ESR) levels [104]. The efficacy of mavrili-
mumab in RA patients was demonstrated in two phase IIa
studies [105,106]. In the Environment and Reproductive
Health (EARTH) study [106], mavrilimumab modulated
the pathophysiological pathways associated with RA,
including acute-phase proteins (CRP and IL-6) and mole-
cules involved in bone damage [matrix metalloproteinase-3
(MMP3)], confirming that GM-CSF acts upstream in the
pathogenesis of RA. A subsequent phase IIb trial (EARTH
EXPLORER 1), demonstrated that mavrilimumab repre-
sented a rapid, effective and well-tolerated potential treat-
ment for RA patients who had previously failed treatment
with conventional disease-modifying anti-rheumatic drugs
(DMARDs), and even biologicals (anti-cytokine therapies)
targeting other inflammatory pathways [107], and this
emphasized an important pathogenic role for the GM-CSF
axis in difficult-to-treat RA. Subsequently, results from the
EARTH EXPLORER 2 trial confirmed that mavrilimumab
was efficacious and well-tolerated in RA patients who were
inadequate responders to both conventional DMARDs and
TNF-inhibitors [108]. Moreover, a subanalysis of the
EARTH EXPLORER 2 trial, conducted to dissect whether
mavrilimumab and golimumab (TNF inhibitor) in both
conventional DMARDs and TNF-inhibitor inadequate
responder RA patients may differ in the modulation of
peripheral biomarkers and pathophysiological pathways,
showed that serum levels of CCL22 and CCL17 were sup-
pressed selectively by mavrilimumab but not golimumab,
while CXCL13 and ICAM1 levels were suppressed by goli-
mumab but not mavrilimumab. These findings suggest
that these two biological DMARDs act on distinct pathways
in patients with RA. This was consistent with animal model
data showing that the pathogenic role of GM-CSF in
arthritis was CCL17-dependent and TNF-independent
[96]. Moreover, mavrilimumab was associated with sus-
tained suppression of other inflammatory markers, includ-
ing vascular endothelial growth factor (VEGF), MMP1 and
MMP3, suggesting its role attenuating aberrant tissue
angiogenesis and structural damage [109]. To date, several
monoclonal antibodies blocking GM-CSF have been devel-
oped: lenzilumab (KB003), gimsilumab (MORAb-022),
MOR103 and namilumab (MT203). MOR103, an IgG1
anti-GM-CSF [110] tested in a randomized phase Ib/IIa,
double-blind, placebo-controlled trial in RA patients,
showed a better clinical response [in terms of disease activ-
ity score in 28 joints (DAS28)] than placebo-treated
patients in a dose-dependent manner, along with a favour-
able safety profile [111].Thus, results to date suggest that
targeting the GM-CSF pathway could be a good treatment
option in RA, particularly for patients not responding to
TNF blockers.
Improving sustained remission in RA patients:
uncovering mediators of remission
The introduction of anti-cytokine therapies for manage-
ment of RA (i.e. TNF inhibitors and anti-IL-6R antibody)
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has revolutionized the wellbeing of patients. However,
despite this progress [112], a significant number of RA
patients do not achieve sustained remission, and this high-
lights the unmet need for therapies with alternative mecha-
nisms of action to treat RA [9]. Moreover, the uncertainty
of disease relapse in RA patients in remission after tapering
or discontinuation of treatment [113–116] strongly sup-
ports the need for a more comprehensive study of the
mediators associated with resolution of inflammation. A
recent elegant paper led by Rauber [116] showed that RA
patients in remission had increased ILC2 producing IL-9 in
circulation and synovium, and that ILC2/IL-9 fostered the
resolution of inflammation and restored joint immune-
homeostasis in experimental arthritis models [116]. Mech-
anistically, they showed that treatment with IL-9 promoted
ILC2-dependent regulatory T cell activation that effectively
induced resolution of inflammation and protection of
bone. These observations suggest that studying mecha-
nisms of remission could provide additional or alternative
targets for RA therapy.
Conclusion
Multiple lines of evidence support the concept that myeloid
cells are key regulators driving the innate immune response
to support chronic, difficult-to-reverse (auto)immune
inflammation in RA. Several inflammatory mediators (i.e.
TNF and GM-CSF) lead to epigenetic reprogramming of
macrophages that promote chronicity within the synovial
tissue. The TNF-enriched synovial environment in concert
with IFN-a may limit the development of myeloid cells tol-
erance to TLR stimuli, and thus prevents the development
of normal homeostatic immune response. GM-CSF, also
enriched in the synovial environment, profoundly activates
myeloid cells by metabolic reprogramming that is critical
for an increase production of proinflammatory cytokines
following TLR restimulation and release of algesic CCL17.
In addition, low expression of anti-inflammatory regula-
tors, e.g. AXL in dendritic cells, driven by a specific epige-
netic signature, leads to high endogenous expression of IL-
6 that may contribute to chronicity of inflammation and
activation of lymphocytes. Future studies investigating the
pathophysiological mechanisms contributing to the perpet-
uation of inflammation in RA will provide a better under-
standing of the transition phase from acute to chronic
inflammation. In addition, a better understanding of
mechanisms of remission could provide alternative ways to
promote resolution of chronic inflammation.
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